[Skip to Content]
[Skip to Content Landing]
Views 110
Citations 0
Research Letter
May 16, 2019

Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification

Author Affiliations
  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 2Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle
  • 3Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 4Department of Biostatistics, University of Washington School of Public Health, Seattle
JAMA Oncol. Published online May 16, 2019. doi:10.1001/jamaoncol.2019.0902

We previously developed and validated the acute myeloid leukemia composite model (AML-CM).1 Our work preceded the development of the European LeukemiaNet (ELN) classification (version 2017) for cytogenetic and/or molecular risks.2 Herein, we revise the design and validation of the AML-CM by using the ELN classification (version 2017). The 2017 ELN classification differs from the 2010 ELN classification used in our original article,1 principally by (1) defining only 3 risk groups (“favorable,” “intermediate,” and “adverse”) rather than 4 groups (with intermediate divided into “intermediate 1” and “intermediate 2”) and (2) including several mutations, such as RUNX1, ASXL1, and TP53, while classifying FLT3 internal tandem duplications according to the proportion of involved alleles (ie, allelic ratio).

×